Skip to main content
. 2019 Dec 2;2(6):e201900603. doi: 10.26508/lsa.201900603

Figure S7. Dose-dependent circadian phase-shifting effects of kinase inhibitors.

Figure S7.

(A, B, C, D) Circadian phase-shifting effects (compared with DMSO control) of (A) KY-05009 (TNIK inhibitor), (B) SU9516 (CDK2 inhibitor), (C) BS-181 HCl (CDK7 inhibitor), and (D) D4476 (CK1d inhibitor) were evaluated by monitoring luminescence rhythms of Bmal1-dLuc U2OS cells. Phase parameter was obtained by curve fitting and plotted against the final concentration of the compounds. Dose–response curves showing the circadian phase shift (phase advancement) at different concentrations of the compounds (33–0.0017 μM, threefold serial dilution). Data are the representative of multiple biological replicates (n = 4, mean ± SEM).